A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide on the Treatment of Nontuberculous Mycobacteria (NTM) Lung Infection in Cystic Fibrosis and Non-Cystic Fibrosis Patients
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Nitric oxide (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Adverse reactions
- Acronyms LungFit GO NTM Trial
- Sponsors Beyond Air
- 15 Apr 2025 New trial record
- 09 Apr 2025 According to Beyond Air media release, this trial was supported by a grant from the U.S. Cystic Fibrosis Foundation
- 09 Apr 2025 According to Beyond Air media release, results from this trial presented in Annals of the American Thoracic Society, an online peer-reviewed journal.